Silo Pharma, Inc. financial data

Symbol
SILO on Nasdaq
Location
Sarasota, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 549% % -28%
Debt-to-equity 39% % 33%
Return On Assets -77% % -59%
Operating Margin -7361% % -31%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13,318,273 shares 197%
Common Stock, Shares, Outstanding 10,461,130 shares 133%
Entity Public Float $3,431,092 USD -42%
Common Stock, Value, Issued $1,046 USD 133%
Weighted Average Number of Shares Outstanding, Basic 9,331,346 shares 117%
Weighted Average Number of Shares Outstanding, Diluted 9,331,346 shares 117%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $72,102 USD 0%
Cost of Revenue $25,066 USD 329%
Research and Development Expense $2,994,368 USD 91%
Operating Income (Loss) $5,307,490 USD -31%
Nonoperating Income (Expense) $230,702 USD -33%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $5,076,788 USD -37%
Net Income (Loss) Attributable to Parent $5,076,788 USD -34%
Earnings Per Share, Basic 0 USD/shares 23%
Earnings Per Share, Diluted 0 USD/shares 23%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $3,917,627 USD -19%
Assets, Current $6,164,369 USD -25%
Intangible Assets, Net (Excluding Goodwill) $220,312 USD -9.8%
Assets $6,384,681 USD -25%
Contract with Customer, Liability, Current $72,102 USD 0%
Liabilities, Current $708,339 USD -32%
Contract with Customer, Liability, Noncurrent $667,502 USD -9.7%
Liabilities $1,375,841 USD -23%
Accumulated Other Comprehensive Income (Loss), Net of Tax $11,345 USD -43%
Retained Earnings (Accumulated Deficit) $18,610,859 USD -38%
Stockholders' Equity Attributable to Parent $5,008,840 USD -26%
Liabilities and Equity $6,384,681 USD -25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,640,300 USD -96%
Net Cash Provided by (Used in) Financing Activities $115,452 USD
Net Cash Provided by (Used in) Investing Activities $871,381 USD 793%
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 10,461,130 shares 133%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3,917,627 USD -19%
Interest Paid, Excluding Capitalized Interest, Operating Activities $2,066 USD 10%
Deferred Tax Assets, Valuation Allowance $3,710,726 USD 46%
Deferred Tax Assets, Gross $3,710,726 USD 46%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $5,085,240 USD -35%
Lessee, Operating Lease, Liability, to be Paid $1,878,928 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $1,878,928 USD
Deferred Tax Assets, Operating Loss Carryforwards $2,958,758 USD 26%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Additional Paid in Capital $23,607,308 USD 16%
Amortization of Intangible Assets $3,092 USD
Share-based Payment Arrangement, Expense $0 USD
Interest Expense $5,084 USD 13%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%